Use of cannabidiol (CBD) for the treatment of chronic pain

Urits, Ivan; Gress, Kyle; Charipova, Karina; Habib, Kelly; Lee, David; Lee, Christopher; Jung, Jai Won; Kassem, Hisham; Cornett, Elyse M.; Paladini, Antonella; Varrassi, Giustino; Kaye, Alan D.; Viswanath, Omar

doi:10.1016/j.bpa.2020.06.004

Cited by 59 publications

(38 citation statements)

References 72 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Recent studies have shown that CBD has promising potential in chronic, neuropathic, and inflammatory pain [82]. Cannabidiol modulates chronic neuropathic pain and depression-specific behavior by activating 5-HT1A and CB1 receptors in the prefrontal cortex, a fact which has been demonstrated in animal models.…”

Section: Cannabidiol (Cbd)-type Compoundsmentioning

confidence: 97%

Major Phytocannabinoids and Their Related Compounds: Should We Only Search for Drugs That Act on Cannabinoid Receptors?

et al. 2021

View full text Add to dashboard Cite

The most important discoveries in pharmacology, such as certain classes of analgesics or chemotherapeutics, started from natural extracts which have been found to have effects in traditional medicine. Cannabis, traditionally used in Asia for the treatment of pain, nausea, spasms, sleep, depression, and low appetite, is still a good candidate for the development of new compounds. If initially all attention was directed to the endocannabinoid system, recent studies suggest that many of the clinically proven effects are based on an intrinsic chain of mechanisms that do not necessarily involve only cannabinoid receptors. Recent research has shown that major phytocannabinoids and their derivatives also interact with non-cannabinoid receptors such as vanilloid receptor 1, transient receptor ankyrin 1 potential, peroxisome proliferator-activated receptor-gamma or glitazone receptor, G55 protein-coupled receptor, and nuclear receptor, producing pharmacological effects in diseases such as Alzheimer’s, epilepsy, depression, neuropathic pain, cancer, and diabetes. Nonetheless, further studies are needed to elucidate the precise mechanisms of these compounds. Structure modulation of phytocannabinoids, in order to improve pharmacological effects, should not be limited to the exploration of cannabinoid receptors, and it should target other courses of action discovered through recent research.

show abstract

Section: Cannabidiol (Cbd)-type Compoundsmentioning

confidence: 97%

Major Phytocannabinoids and Their Related Compounds: Should We Only Search for Drugs That Act on Cannabinoid Receptors?

et al. 2021

View full text Add to dashboard Cite

show abstract

“…Although Cannabis sativa varieties synthesize >100 different cannabinoids, two compounds, D 9 -tetrahydrocannabinol (THC) and cannabidiol (CBD), are primarily studied for their clinical effects. Cannabis extracts and individual cannabinoids are increasingly used in patients suffering from glaucoma, neuropathic pain, and cancer (95,96). THC is known for its appetite stimulation and psychoactive properties and is a Schedule 1-controlled substance.…”

Section: Cannabinoidsmentioning

confidence: 99%

“…In contrast, CBD is non-psychoactive and has analgesic, anxiolytic, and anticonvulsant properties (95,96). In the U.S., chemically-synthesized CBD is legally sold as an over-thecounter supplement.…”

Section: Cannabinoidsmentioning

confidence: 99%

Neurofibromatosis: Molecular Pathogenesis and Natural Compounds as Potential Treatments

et al. 2021

View full text Add to dashboard Cite

The neurofibromatosis syndromes, including NF1, NF2, and schwannomatosis, are tumor suppressor syndromes characterized by multiple nervous system tumors, particularly Schwann cell neoplasms. NF-related tumors are mainly treated by surgery, and some of them have been treated by but are refractory to conventional chemotherapy. Recent advances in molecular genetics and genomics alongside the development of multiple animal models have provided a better understanding of NF tumor biology and facilitated target identification and therapeutic evaluation. Many targeted therapies have been evaluated in preclinical models and patients with limited success. One major advance is the FDA approval of the MEK inhibitor selumetinib for the treatment of NF1-associated plexiform neurofibroma. Due to their anti-neoplastic, antioxidant, and anti-inflammatory properties, selected natural compounds could be useful as a primary therapy or as an adjuvant therapy prior to or following surgery and/or radiation for patients with tumor predisposition syndromes, as patients often take them as dietary supplements and for health enhancement purposes. Here we review the natural compounds that have been evaluated in NF models. Some have demonstrated potent anti-tumor effects and may become viable treatments in the future.

show abstract

“…5-In recent years, emerging drug therapies for chronic pain have been proposed and supported by communities, including the medical use of cannabis (11)(12)(13). But some cumbersome laws have prevented these new treatments from becoming common in developing countries.…”

Section: -Proper Pain Control Needs Appropriate Assessmentmentioning

confidence: 99%

Evolution of Interventional Pain Management and Its Barriers in Developing Countries

Hashemi

Aminnejad

Rajaei

2021

Interv Pain Med Neuromod

View full text Add to dashboard Cite

Use of cannabidiol (CBD) for the treatment of chronic pain

Cited by 59 publications

References 72 publications

Major Phytocannabinoids and Their Related Compounds: Should We Only Search for Drugs That Act on Cannabinoid Receptors?

Major Phytocannabinoids and Their Related Compounds: Should We Only Search for Drugs That Act on Cannabinoid Receptors?

Neurofibromatosis: Molecular Pathogenesis and Natural Compounds as Potential Treatments

Evolution of Interventional Pain Management and Its Barriers in Developing Countries

Contact Info

Product

Resources

About